Klin Farmakol Farm. 2004;18(1):51-52

COMET - Carvedilol or Metoprolol European Trial - mortalitní studie srovnávající dva betablokátory u srdečního selhání

Jiří Vítovec1, doc. MUDr. Jindřich ©pinar CSc2
1 I. interní kardioangiologická klinika FN u sv. Anny v Brně
2 II. interní klinika FN u sv. Anny LF MU, Brno

Keywords: congestive heart failure, carvedilol, metoprolol.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. COMET - Carvedilol or Metoprolol European Trial - mortalitní studie srovnávající dva betablokátory u srdečního selhání. Klin Farmakol Farm. 2004;18(1):51-52.

Podán rozbor studie COMET, uvedena charakteristika souboru a výsledky, kdy carvedilol v dávce 42 mg měl niľąí úmrtnost neľ neretardovaný metoprolol v dávce 85 mg.

COMET - carvedilol or metoprolol european trial

Presented study COMET, baseline charakteristics and results. Carvedilol (mean dose 42 mg) extended survival compared with metoprolol (mean dose 85 mg).

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams KF Jr. Which beta-blocker for heart failure? Am Heart J 2001; 141: 884-888. Go to original source... Go to PubMed...
    2. Andersson B, Aberg J, Lindelow B, et al. Dose-Related Effects of Metoprolol on Heart Rate and Pharmacokinetics in Heart Failure. J Cardiac Failure 2001; 7: 311-317. Go to original source... Go to PubMed...
    3. BEST Trial Investigators. A trial of beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667. Go to original source... Go to PubMed...
    4. CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390. Go to original source... Go to PubMed...
    5. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9-13. Go to original source...
    6. Di Lenarda A, De Maria R, Gavazzi A, et al. Metoprolol in Idiopatic Dilated Cardiomyopathy. Heart 1998; 79: 337-344. Go to original source... Go to PubMed...
    7. Johnsson G, Jrdo L, Lundborg P, et al. Plasma levels and Pharmacological effects of metoprolol administered as controlled release(Durules) and ordinary tablets in healthy volunteers. Int J Clin Pharmacol Ther Tox 1980; 18: 292-297.
    8. Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 2000; 35: 45-50. Go to original source... Go to PubMed...
    9. Kukin ML, Kalman J, Charney RH, et al. Prospective randomised comparison of the effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Curculation 1999; 99: 2645-2651. Go to original source... Go to PubMed...
    10. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. Engl J Med 2001; 344: 1651-1658. Go to original source... Go to PubMed...
    11. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of meta-analysis. Am Heart J 2001; 141: 899-907. Go to original source... Go to PubMed...
    12. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A. For the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13. Go to original source... Go to PubMed...
    13. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and Pharmacodynamic Properties of a New Controlled Release Formulation of Metoprolol: A Comparison with Conventional tablets. Eur J Clin Pharmacol 1988; 33 (suppl): S9-S14. Go to original source... Go to PubMed...
    14. ©pinar J, Vítovec J. Euro Heart Survey - Heart Failure Cor Vasa 2001; 43: K202.
    15. The MERIT-HF Study Group: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart failure (MERIT-HF). Mortality study. Lancet 1999; 353: 2001-2007. Go to original source...
    16. Vítovec J, ©pinar J. Jsou betablokátory v léčbě srdečního selhání stejně účinné? CorVasa 2002; 44: 209-210.
    17. Vítovec J, ©pinar J. Který betablokátor u srdečního selhání. Studie COMET dala jasnou odpověď? Cor vasa 2003, 45: 527-528.
    18. Waagstein F, Bristol MR, Swedberg K, et al. Metoprolol in Dilated Cardiomyopathy. Lancet 1993; 342: 1441-1446. Go to original source... Go to PubMed...
    19. Widimský J, Lánská V, Magulová D, Sachová M. Průzkum stavu aktuální praxe diagnostiky a léčby srdečního selhání v ordinacích vąeobecných lékařů v České a Slovenské republice v roce 1999. Cor Vasa 2001; 43: 345-352.
    20. Widimský J. Beta-blokátory v léčbě chronického srdečního selhání Kap Kardiol 2003; 5: 122-126.
    21. Wieselgren I, Lundborg P, Sandberg A, et al. Pharmacokinetic and Pharmacodynamic Evaluation of Metoprolol Controlled Release (CR/ZOK) 50 mg in Young Subjects. J. Clin. Pharmacol 1990; 30 (Suppl): S28-S32. Go to original source... Go to PubMed...
    22. Wikstrand J, Anderson B, Kendall MJ, et al. Pharmacokinetic Considerations of Formulation: Extended-Release Metoprolol Succinate in the Treatment of Heart Failure. J Cardiovasc Pharmacol 2003; 41: 151-157. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.